Sensei Biotherapeutics (NASDAQ:SNSE) Coverage Initiated by Analysts at Leerink Partners

Stock analysts at Leerink Partners started coverage on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a research report issued to clients and investors on Monday. The brokerage set an “outperform” rating and a $50.00 price target on the stock. Leerink Partners’ price objective points to a potential upside of 63.99% from the company’s previous close.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Sensei Biotherapeutics Price Performance

SNSE opened at $30.49 on Monday. The stock’s 50 day moving average price is $27.44 and its two-hundred day moving average price is $16.02. The firm has a market capitalization of $40.86 million, a P/E ratio of -1.83 and a beta of -0.10. Sensei Biotherapeutics has a 12-month low of $5.25 and a 12-month high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings results on Monday, March 30th. The company reported ($3.74) EPS for the quarter, beating the consensus estimate of ($4.81) by $1.07. As a group, analysts anticipate that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.